全文获取类型
收费全文 | 207457篇 |
免费 | 39123篇 |
国内免费 | 6978篇 |
专业分类
耳鼻咽喉 | 5621篇 |
儿科学 | 5915篇 |
妇产科学 | 2946篇 |
基础医学 | 10169篇 |
口腔科学 | 2650篇 |
临床医学 | 34355篇 |
内科学 | 55650篇 |
皮肤病学 | 7853篇 |
神经病学 | 17991篇 |
特种医学 | 8478篇 |
外国民族医学 | 52篇 |
外科学 | 46715篇 |
综合类 | 11296篇 |
现状与发展 | 91篇 |
一般理论 | 5篇 |
预防医学 | 11069篇 |
眼科学 | 5139篇 |
药学 | 7649篇 |
38篇 | |
中国医学 | 3455篇 |
肿瘤学 | 16421篇 |
出版年
2023年 | 5742篇 |
2022年 | 2627篇 |
2021年 | 5995篇 |
2020年 | 8539篇 |
2019年 | 4337篇 |
2018年 | 9521篇 |
2017年 | 9337篇 |
2016年 | 10281篇 |
2015年 | 11291篇 |
2014年 | 19028篇 |
2013年 | 18599篇 |
2012年 | 10195篇 |
2011年 | 10581篇 |
2010年 | 13349篇 |
2009年 | 16525篇 |
2008年 | 8979篇 |
2007年 | 7084篇 |
2006年 | 9509篇 |
2005年 | 6755篇 |
2004年 | 4934篇 |
2003年 | 3872篇 |
2002年 | 3608篇 |
2001年 | 5137篇 |
2000年 | 4408篇 |
1999年 | 4820篇 |
1998年 | 4598篇 |
1997年 | 4326篇 |
1996年 | 4023篇 |
1995年 | 3837篇 |
1994年 | 2573篇 |
1993年 | 1949篇 |
1992年 | 1911篇 |
1991年 | 1826篇 |
1990年 | 1441篇 |
1989年 | 1494篇 |
1988年 | 1324篇 |
1987年 | 1081篇 |
1986年 | 1094篇 |
1985年 | 891篇 |
1984年 | 639篇 |
1983年 | 574篇 |
1982年 | 552篇 |
1981年 | 434篇 |
1980年 | 373篇 |
1979年 | 348篇 |
1978年 | 343篇 |
1977年 | 410篇 |
1975年 | 284篇 |
1972年 | 282篇 |
1970年 | 257篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
41.
42.
43.
44.
45.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
46.
Wuteng Cao Huabin Hu Jiao Li Qianyu Wu Lishuo Shi Biao Li Jie Zhou Xinhua Wang Junhong Chen Chao Wang Huaiming Wang Weihao Deng Yan Huang Yanhong Deng 《International journal of cancer. Journal international du cancer》2023,153(11):1894-1903
Neoadjuvant programmed cell death protein 1 (PD-1) blockade exhibits promising efficacy in patients with mismatch repair deficient (dMMR) colorectal cancer (CRC). However, discrepancies between radiological and histological findings have been reported in the PICC phase II trial (NCT 03926338). Therefore, we strived to discern radiological features associated with pathological complete response (pCR) based on computed tomography (CT) images. Data were obtained from the PICC trial that included 36 tumors from 34 locally advanced dMMR CRC patients, who received neoadjuvant PD-1 blockade for 3 months. Among the 36 tumors, 28 (77.8%) tumors achieved pCR. There were no statistically significant differences in tumor longitudinal diameter, the percentage change in tumor longitudinal diameter from baseline, primary tumor sidedness, clinical stage, extramural venous invasion status, intratumoral calcification, peritumoral fat infiltration, intestinal fistula and tumor necrosis between the pCR and non-pCR tumors. Otherwise, tumors with pCR had smaller posttreatment tumor maximum thickness (median: 10 mm vs 13 mm, P = .004) and higher percentage decrease in tumor maximum thickness from baseline (52.9% vs 21.6%, P = .005) compared to non-pCR tumors. Additionally, a higher proportion of the absence of vascular sign (P = .003, odds ratio [OR] = 25.870 [95% CI, 1.357-493.110]), nodular sign (P < .001, OR = 189.000 [95% CI, 10.464-3413.803]) and extramural enhancement sign (P = .003, OR = 21.667 [2.848-164.830]) was observed in tumors with pCR. In conclusion, these CT-defined radiological features may have the potential to serve as valuable tools for clinicians in identifying patients who have achieved pCR after neoadjuvant PD-1 blockade, particularly in individuals who are willing to adopt a watch-and-wait strategy. 相似文献
47.
Osnat Bairey MD Alisa Taliansky MD Amir Glik MD Alexandra Amiel MD Shlomit Yust-Katz MD Ronit Gurion MD Miri Zektser MD Tzvika Porges MD Nadav Sarid MD Netanel A. Horowitz MD Tzahala Tzuk Shina MD Eyal Lebel MD Amos Cohen MD Karyn Revital Geiger MD Pia Raanani MD Ofir Wolach MD Tali Siegal MD 《Cancer》2023,129(24):3905-3914
48.
The advent of precision medicine has changed the landscape of oncologic biomarkers, drug discovery, drug development, and, more importantly, outcomes for patients with cancer. Precision oncology entails the genomic profiling of tumors to detect actionable aberrations. The advances in clinical next-generation sequencing from both tumor tissue and liquid biopsy and availability of targeted therapies has rapidly entered mainstream clinical practice. In this review, recent major developments in precision oncology that have affected outcomes for patients with cancer are discussed. Rapid clinical development was seen of targeted agents across various mutational profiles such as KRASG12C (which was considered “undruggable” for almost 4 decades), Exon 20 insertions, and RET mutations. Approaches to precision chemotherapy delivery by the introduction of antibody drug conjugates in the armamentarium against lung cancer has been appreciated. 相似文献
49.
- Children with cancer receive many medications outside the hospital administered by their caregivers.
- The study by Walsh et al. shows the number and types of medication errors in these patients. The study includes data from three different centers.
- Importantly, the study shows the types of errors that cause harm. The authors describe how the harmful errors can be prevented.
- We suggest ways these results can be used to identify which patients and families will benefit from additional attention. Providing more help at clinic and in the home may help prevent harmful medication errors in children with cancer.
50.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献